BIOMAT Database Logo BIOMAT Database Logo

Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1 microg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. 2004

M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
Division of Physical Medicine and Rehabilitation, Department of Medical Sciences, University of Erciyes, Kayseri, Turkey.

Primary fibromyalgia syndrome (PFS) is characterized by widespread chronic pain that affects the musculoskeletal system, fatigue, anxiety, sleep disturbance, headache and postural hypotension. The pathophysiology of PFS is unknown. The hypothalamic-pituitary-adrenal (HPA) axis seems to play an important role in PFS. Both hyperactivity and hypoactivity of the HPA axis have been reported in patients with PFS. In this study we assessed the HPA axis by 1 microg ACTH stimulation test and metyrapone test in 22 patients with PFS and in 15 age-, sex-, and body mass index (BMI)- matched controls. Metyrapone (30 mg/kg) was administered orally at 23:00 h and blood was sampled at 08:30 h the following morning for 11-deoxycortisol. ACTH stimulation test was carried out by using 1 microg (iv) ACTH as a bolus injection after an overnight fast, and blood samples were drawn at 0, 30 and 60 min. Peak cortisol level (659.4 +/- 207.2 nmol/l) was lower in the patients with PFS than peak cortisol level (838.7 +/- 129.6 nmol/l) in the control subjects (p < 0.05). Ten patients (45%) with PFS had peak cortisol responses to 1 microg ACTH test lower than the lowest peak cortisol detected in healthy controls. After metyrapone test 11-deoxycortisol level was 123.7 +/- 26 nmol/l in patients with PFS and 184.2 +/- 17.3 nmol/l in the controls (p < 0.05). Ninety five percent of the patients with PFS had lower 11-deoxycortisol level after metyrapone than the lowest 11-deoxycortisol level after metyrapone detected in healthy controls. We also compared the adrenal size of the patients with that of the healthy subjects and we found that the adrenal size between the groups was similar. This study clearly shows that HPA axis is underactivated in PFS, rather than overactivated.

UI MeSH Term Description Entries
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D008297 Male Males
D008797 Metyrapone An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME. Methbipyranone,Methopyrapone,Metopiron,Metopirone,Métopirone,SU 4885
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003350 Cortodoxone 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities. 11-Deoxycortisol,11-Desoxycortisone,Cortexolone,11-Desoxycortisol,Reichstein's Substance S,11 Deoxycortisol,11 Desoxycortisol,11 Desoxycortisone,Reichstein Substance S,Reichsteins Substance S,Substance S, Reichstein's
D005260 Female Females
D005356 Fibromyalgia A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95) Diffuse Myofascial Pain Syndrome,Fibrositis,Rheumatism, Muscular,Fibromyalgia, Primary,Fibromyalgia, Secondary,Fibromyalgia-Fibromyositis Syndrome,Fibromyositis-Fibromyalgia Syndrome,Myofascial Pain Syndrome, Diffuse,Fibromyalgia Fibromyositis Syndrome,Fibromyalgia-Fibromyositis Syndromes,Fibromyalgias,Fibromyalgias, Primary,Fibromyalgias, Secondary,Fibromyositis Fibromyalgia Syndrome,Fibromyositis-Fibromyalgia Syndromes,Fibrositides,Muscular Rheumatism,Primary Fibromyalgia,Primary Fibromyalgias,Secondary Fibromyalgia,Secondary Fibromyalgias,Syndrome, Fibromyalgia-Fibromyositis,Syndrome, Fibromyositis-Fibromyalgia,Syndromes, Fibromyalgia-Fibromyositis,Syndromes, Fibromyositis-Fibromyalgia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
A comparison between low-dose (1 microg), standard-dose (250 microg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitary-adrenal axis in primary fibromyalgia syndrome.
October 2001, Clinical endocrinology,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
The low dose (1 microg) ACTH stimulation test for assessment of the hypothalamo-pituitary-adrenal axis.
March 2000, The Netherlands journal of medicine,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
A comparison between the 1-microg adrenocorticotropin (ACTH) test, the short ACTH (250 microg) test, and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery.
October 2000, The Journal of clinical endocrinology and metabolism,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.
June 2021, Reviews in endocrine & metabolic disorders,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis.
January 2003, Journal of endotoxin research,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis.
June 2003, Minerva endocrinologica,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome.
March 2007, Stress (Amsterdam, Netherlands),
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
Circadian rhythms in the hypothalamo-pituitary-adrenal (HPA) axis.
February 2012, Molecular and cellular endocrinology,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
Human studies on hypothalamo-pituitary-adrenal (HPA) axis.
October 2017, Best practice & research. Clinical endocrinology & metabolism,
M Calis, and C Gökçe, and F Ates, and S Ulker, and H B Izgi, and H Demir, and M Kirnap, and S Sofuoglu, and A C Durak, and A Tutus, and F Kelestimur
Low dose (1 microg) adrenocorticotropin stimulation test in the evaluation of hypothalamo-pituitary-adrenal axis in patients with active pulmonary tuberculosis.
April 2000, Journal of endocrinological investigation,
Copied contents to your clipboard!